Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
2096.HK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.22
-17%
0.18
vs 0.22
Q4.22
-15%
0.19
vs 0.22
Q1.23
+3189%
0.49
vs 0.02
Q2.23
+3180%
0.47
vs 0.01
Q3.23
N/A
-0.32
vs 0.18
Q4.23
N/A
-0.33
vs 0.19
Q1.24
-80%
0.1
vs 0.49
Q2.24
-79%
0.1
vs 0.47
Q3.24
+119%
0.06
vs -0.32
Q4.24
+118%
0.06
vs -0.33
Sales Growth
YoY
Current
Estimates
Q3.22
+26%
1.8B vs 1.4B
Q4.22
+26%
1.8B vs 1.4B
Q1.23
+25%
1.7B vs 1.3B
Q2.23
+25%
1.7B vs 1.3B
Q3.23
-11%
1.6B vs 1.8B
Q4.23
-11%
1.6B vs 1.8B
Q1.24
-8%
1.6B vs 1.7B
Q2.24
-8%
1.6B vs 1.7B
Q3.24
+9%
1.8B vs 1.6B
Q4.24
+9%
1.8B vs 1.6B
Return on Equity
QoQ
Q1.23
+13%
0.13
vs 0.06
Q2.23
+13%
0.13
vs 0.13
Q3.23
-11%
-0.11
vs 0.13
Q4.23
-11%
-0.11
vs -0.11
Q1.24
+3%
0.03
vs -0.11
Q2.24
+3%
0.03
vs 0.03
Q3.24
+2%
0.02
vs 0.03
Q4.24
+2%
0.02
vs 0.02
Institutionnal Ownership
Relative Strength
2096.HK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.
HKSE
-0.70Â ( -5.97%)
Relative Strenght
Volume Buzz
398%
Earning Acce
No
Dist 52w H.
18%Forecast
374%2025-Revenue
804%2025-EPS
356%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 2096.HK compares to sector?